PTC Therapeutics (PTCT) Stock: Here’s What You Need To Know

PTC Therapeutics (NASDAQ:PTCT) On Monday, PTC Therapeutics fell by 40% to $7.97 per share after the company had announced that the FDA refused its appeal for a refuse-to-file letter. PTC Therapeutics has not been able to get the FDA to back its Duchenne Muscular Dystrophy — DMD — drug. What happened was that PTC had … Read more

Sarepta Therapeutics (SRPT) Stock: Here’s What You Need To Know

Sarepta Therapeutics (NASDAQ:SRPT) On Monday, Sarepta’s stock closed the day up 73.85% after the company announced that the FDA had given its drug Eteplirsen FDA approval. More specifically, the company filed for accelerated approval. In other words, drugs can be approved after only completing a phase 2 study if the results show that a surrogate … Read more

Biotech Stock News (SRPT)(SPHS)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday June 6, 2016 shares of Sarepta Therapeutics were up more than 31% in after-hours trade after the company announced that the FDA had requested for additional data for the Eteplirsen decision. The market clearly viewed the fact that the FDA needed more data as a positive. Which is why shares … Read more

Biotech Stock News (STEM) (SRPT)

StemCells Inc. (NASDAQ:STEM) On Tuesday May 31, 2016 shares of Stemcells fell by more than 83% after the company announced that it would completely stop its phase 2 Pathway study. The phase 2 study used Stem’s HuCNS-SC human neural stem cells to treat spinal cord injury. This was a huge shock for investors, because the … Read more

Biotech Stock News (SRPT) (BMRN) (ACAD)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday April 25, 2016 Sarepta Therapeutics had an FDA advisory panel shoot down its drug Eteplirsen, used to treat patients with Duchenne Muscular Dystrophy — DMD. The panel voted against Eteplirsen on all questions. Even the last question which asked if Eteplirsen should be approved for DMD patients was also voted … Read more

Biotech Stock News (RXII) (SRPT)

Rxi Pharmaceuticals (NASDAQ:RXII) On Tuesday April 19, 2016 Rxi Pharmaceuticals announced that it would present pre-clinical data at a medical conference, known as 2016 ARVO Conference. ARVO stands for Association for Research in Vision and Ophthalmology. The pre-clinical data to be presented will be the company’s drug in corneal scarring. In order to prevent injury … Read more

Biotech Stock News (CLDX) (SRPT)

Celldex Therapeutics (NASDAQ:CLDX) On Monday March 7, 2016 shares of Celldex fell as much as 53% after the company announced that it had to discontinue a phase 3 trial. The reason for discontinuing the trial was because of insufficient efficacy needed to move on. This phase 3 trial recruited a total of 745 patients who … Read more

Biotech Stock News (CMRX) (PTCT) (SRPT) (BMRN) (PPHM)

Chimerix (NASDAQ:CMRX)¬† On Monday February 22, 2016 shares of Chimerix tumbled by 40% as the company announced that two phase 3 trials had to be stopped because of lack of efficacy. The phase 3 trial, known as the SUPPRESS trial, recruited a total of 452 patients. The patients that were recruited in the trial were … Read more

Biotech Stock News (ARNA) (BMRN) (SRPT)

Arena Pharmaceuticals (NASDAQ:ARNA) On Tuesday January 12, 2016 Arena Pharmaceuticals announced a collaboration with a privately held pharmaceuticals company, known as Boehringer Ingelheim — BI. This research collaboration is an early one targeting G-coupled protein receptors. These types of protein receptors go after several types of Central Nervous System — CNS — disorders. Arena is … Read more

Biotech Stock News (SRPT) (JUNO) (CELG) (AGTC) (VRTX)

Sarepta Therapeutics (NASDAQ:SRPT) On Monday June 29, 2015 Sarepta had announced that it had completed¬†its rolling submission of its New Drug Application — NDA — to the FDA. A rolling submission is an FDA policy whereby biotech companies can submit their marketing approval application in small parts on a rolling basis instead of doing it … Read more